Establishing a global vaccine-development fund

New England Journal of Medicine

Volumn 373, Issue 4, 2015, Pages 297-300

  Plotkin, Stanley A ^a,b   Mahmoud, Adel A F ^b,c   Farrar, Jeremy ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Foundation for Vaccine Research   (United States)

^c PRINCETON UNIVERSITY   (United States)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; VACCINE;

DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; FUNDING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INVESTMENT; LICENSING; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; DRUG DEVELOPMENT; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH;

DRUG DISCOVERY; DRUG INDUSTRY; GLOBAL HEALTH; HUMANS; RESEARCH SUPPORT AS TOPIC; VACCINES;

EID: 84937857841     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1506820     Document Type: Article

References (4)

1. Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines 2014;13:521-31.
2. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010;29:304-13.
3. Pronker ES, Weenen TC, Commandeur HR, Osterhaus AD, Claassen HJ. The gold industry standard for risk and cost of drug and vaccine development revisited. Vaccine 2011;29:5846-9.
4. Pronker ES, Weenen TC, Commandeur HR, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PLoS One 2013;8(3):e57755.